Check out our free and informative ezines and sign up now
GlaxoSmithKline (GSK) has resumed U.S. sales of Paxil CR — a move that comes roughly four months after the firm voluntarily halted production of the antidepressant because of quality concerns.
This article is viewable by subscribers only. To view this article, please select an option below.
ePublishing :: CMS, Hosting & Web Development | © Copyright